Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Nutritional-GIClosed to enrollment Location: USA

    Vitamin D for enhancing the immune system in people with CF , protocol number TANGPR11A0

    This multi-centre trial will look at the effect of a one time high-dose vitamin D to rapidly correct vitamin D deficiency in people with CF who are over 16 years of age admitted to the hospital for pulmonary exacerbation.

    • Age:

      16 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      20% or greater

    • Number of Visits:

      6

    • Length of Participation:

      1 year

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15

    This phase 2 study is taking place at multiple care centers across the US. It will look at the effect of adding oral azithromycin to inhaled tobramycin and will use placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      6

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveClosed to enrollment Location: USA

    Arikace compared to TobiĀ® in people with CF with chronic Pseudomonas aueruginosa infections , protocol number Insmed TR02-108

    This study took place at multiple care centres across the US. It looked at the effectiveness, safety and tolerability of Arikace compared to TOBI, an inhalation antibiotic already available for use.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% or greater

    • Number of Visits:

      11

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Efficacy and Safety of Ultrase MT20 in Children with CF and Pancreatic Insufficiency , protocol number Axcan UMT20CF07-01

    This study looked at the effectiveness and safety of pancrelipase (ULTRASE MT20) in children who have CF and pancreatic insufficiency.

    • Age:

      7 Years to 11 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      33 days

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Use of Utrase MT 12 Enzymes in Young Children with CF Related Pancreatic Insufficiency , protocol number Axcan UMT12CF08-01

    This study evaluated the safety and effectiveness of pancrelipase (Ultrase MT 12) in young children with CF.

    • Age:

      2 Years to 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      4

    • Length of Participation:

      30 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of lumacaftor and ivacaftor in children with CF , protocol number Vertex VX13-809-011a

    This study is taking place at multiple care centers across the U.S. It looked at the safety of lumacaftor in combination with ivacaftor, as well as how the body processes the drugs, in children with CF.

    • Age:

      6 Years to 11 Years

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      24 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    Phase 3 study of lumacaftor/ivacaftor in children with CF , protocol number Vertex VX15-809-115

    This two-part, open-label study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of lumacaftor/ivacaftor as well as how the body processes the drug, in children with CF.

    • Age:

      2 - 5 Years

    • Mutation(s):

      Two Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      11

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 2 study of VX-659 combination drug in adults with cystic fibrosis. , protocol number VX16-659-101

    This study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of the drug VX-659.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      6

    • Length of Participation:

      8 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    A Study to evaluate tezacaftor/ivacaftor and ivacaftor in adults with cystic fibrosis and two copies of the F508del mutation. , protocol number NCT031 50719 VX16-661-114

    This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety, effectiveness, and tolerability of the drug tezacaftor/ivacaftor in combination with ivacaftor.

    • Age:

      12 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      25% - 90%

    • Number of Visits:

      5

    • Length of Participation:

      84 days

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: USA

    Phase 2 study of VX-371 in people with CF who are currently taking lumacaftor/ivacaftor , protocol number Vertex VX-371-101

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the inhaled drug VX-371 (formerly P-1037) and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      12

    • Length of Participation:

      98 days

    Contact us about this clinical Trial >
  • Displaying results 121-130 (of 142)
     |<  <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >  >|